PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PRME vs. CRBP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PRME and CRBP is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

PRME vs. CRBP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-24.42%
-86.09%
PRME
CRBP

Key characteristics

Sharpe Ratio

PRME:

-0.75

CRBP:

-0.60

Sortino Ratio

PRME:

-1.10

CRBP:

-0.38

Omega Ratio

PRME:

0.88

CRBP:

0.94

Calmar Ratio

PRME:

-0.71

CRBP:

-0.66

Martin Ratio

PRME:

-1.22

CRBP:

-1.29

Ulcer Index

PRME:

51.76%

CRBP:

49.65%

Daily Std Dev

PRME:

84.09%

CRBP:

106.41%

Max Drawdown

PRME:

-89.20%

CRBP:

-99.31%

Current Drawdown

PRME:

-85.18%

CRBP:

-97.33%

Fundamentals

Market Cap

PRME:

$430.86M

CRBP:

$95.00M

EPS

PRME:

-$2.06

CRBP:

-$4.71

Total Revenue (TTM)

PRME:

$38.57M

CRBP:

$0.00

Gross Profit (TTM)

PRME:

$37.26M

CRBP:

-$351.69K

EBITDA (TTM)

PRME:

-$153.83M

CRBP:

-$31.87M

Returns By Period

In the year-to-date period, PRME achieves a 7.19% return, which is significantly higher than CRBP's -29.83% return.


PRME

YTD

7.19%

1M

7.56%

6M

-24.40%

1Y

-63.13%

5Y*

N/A

10Y*

N/A

CRBP

YTD

-29.83%

1M

-30.60%

6M

-86.09%

1Y

-69.50%

5Y*

-45.12%

10Y*

-18.67%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PRME vs. CRBP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME
The Risk-Adjusted Performance Rank of PRME is 1111
Overall Rank
The Sharpe Ratio Rank of PRME is 1010
Sharpe Ratio Rank
The Sortino Ratio Rank of PRME is 99
Sortino Ratio Rank
The Omega Ratio Rank of PRME is 1313
Omega Ratio Rank
The Calmar Ratio Rank of PRME is 88
Calmar Ratio Rank
The Martin Ratio Rank of PRME is 1515
Martin Ratio Rank

CRBP
The Risk-Adjusted Performance Rank of CRBP is 1616
Overall Rank
The Sharpe Ratio Rank of CRBP is 1616
Sharpe Ratio Rank
The Sortino Ratio Rank of CRBP is 2323
Sortino Ratio Rank
The Omega Ratio Rank of CRBP is 2222
Omega Ratio Rank
The Calmar Ratio Rank of CRBP is 1010
Calmar Ratio Rank
The Martin Ratio Rank of CRBP is 1111
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PRME vs. CRBP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Corbus Pharmaceuticals Holdings, Inc. (CRBP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for PRME, currently valued at -0.75, compared to the broader market-2.000.002.00-0.75-0.60
The chart of Sortino ratio for PRME, currently valued at -1.10, compared to the broader market-4.00-2.000.002.004.006.00-1.10-0.38
The chart of Omega ratio for PRME, currently valued at 0.88, compared to the broader market0.501.001.502.000.880.94
The chart of Calmar ratio for PRME, currently valued at -0.71, compared to the broader market0.002.004.006.00-0.71-0.73
The chart of Martin ratio for PRME, currently valued at -1.22, compared to the broader market-10.000.0010.0020.0030.00-1.22-1.29
PRME
CRBP

The current PRME Sharpe Ratio is -0.75, which is comparable to the CRBP Sharpe Ratio of -0.60. The chart below compares the historical Sharpe Ratios of PRME and CRBP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.75
-0.60
PRME
CRBP

Dividends

PRME vs. CRBP - Dividend Comparison

Neither PRME nor CRBP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PRME vs. CRBP - Drawdown Comparison

The maximum PRME drawdown since its inception was -89.20%, smaller than the maximum CRBP drawdown of -99.31%. Use the drawdown chart below to compare losses from any high point for PRME and CRBP. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-85.18%
-86.55%
PRME
CRBP

Volatility

PRME vs. CRBP - Volatility Comparison

The current volatility for Prime Medicine Inc. Common Stock (PRME) is 26.13%, while Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a volatility of 29.16%. This indicates that PRME experiences smaller price fluctuations and is considered to be less risky than CRBP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
26.13%
29.16%
PRME
CRBP

Financials

PRME vs. CRBP - Financials Comparison

This section allows you to compare key financial metrics between Prime Medicine Inc. Common Stock and Corbus Pharmaceuticals Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab